Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lehman: AZT/3TC/NVP vs Short Course AZT/sdNVP Maternal Resistance · HIV‐Infected Pregnant Women With CD4 Counts 200‐500 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.24 [0.07, 0.88] | 1 study · 27 participants | Very low |
Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC Infant Mortality at 6 Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.95 [0.34, 2.68] | 1 study · 553 participants | Low |
Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC Women With Any Grade 3/4 Severe Adverse Event (Laboratory Only) · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.79 [0.51, 1.21] | 1 study · 560 participants | Very low |
Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC Women With Any Severe Adverse Events Requiring Treatment Modification · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.89 [0.3, 2.61] | 1 study · 560 participants | Very low |
Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC Infants With Any Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.13 [0.93, 1.37] | 1 study · 553 participants | Low |
Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC Prematurity · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.52 [1.07, 2.17] | 1 study · 553 participants | Low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant HIV Transmission or Death at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.64 [0.44, 0.92] | 1 study · 765 participants | Very low |
Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC Infant Low Birth Weight · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.27 [0.85, 1.91] | 1 study · 553 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Stillbirths · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.65 [0.21, 1.96] | 1 study · 560 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Maternal Mortality at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.35 [0.01, 8.44] | 1 study · 560 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Mother to Child Transmission In Utero Positive HIV DNA PCR Within 96 Hours · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.35 [0.04, 3.34] | 1 study · 553 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Mother to Child Transmission Late Postpartum Negative HIV DNA PCR at Birth and One Month, But Positive HIV DNA PCR at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.21 [0.01, 4.35] | 1 study · 553 participants | Low |
Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC Mother to Child Transmission at Six Months Post‐Partum All Positive HIV DNA PCRs at Six Months · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.17 [0.02, 1.44] | 1 study · 553 participants | Low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) HIV‐Transmission or Death at 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.39 [0.18, 0.85] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Infant Grade 3/4 Severe Adverse Events at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.26 [0.35, 4.54] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Prematurity · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.56 [0.21, 1.5] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Mother to Child Transmission at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.18 [0.02, 1.36] | 1 study · 178 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.78 [0.43, 1.42] | 1 study · 781 participants | Moderate |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Mother to Child Transmission at 1 Month · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.23 [0.05, 0.96] | 1 study · 178 participants | Very low |
Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) Mother to Child Transmission Cumulative by 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.15 [0.04, 0.62] | 1 study · 178 participants | Very low |
Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen Stillbirths · ART‐Eligible HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.16 [0.34, 3.93] | 1 study · 326 participants | Very low |
Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen Infant Low Birth Weight · ART‐Eligible HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.81 [1.09, 3] | 1 study · 309 participants | Very low |
Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen Mother to Child Transmission at 12 Months · ART‐Eligible HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.14 [0.04, 0.47] | 1 study · 311 participants | Very low |
Jamisse (What to Start): AZT/3TC/NVP vs d4T/3TC/NVP Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4<350 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.58 [0.6, 4.12] | 1 study · 146 participants | Very low |
Jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 vs AZT/3TC/NVP Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women1 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.18 [0.47, 2.97] | 1 study · 146 participants | Very low |
Marazzi: AZT/3TC/NVP for HIV Infection in Pregnant Women With CD4 <250 vs >250 cells/mm3 Maternal Grade 3/4 Hepatotoxicity · HIV‐infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.64 [0.34, 1.2] | 1 study · 703 participants | Ungraded |
Phanuphak: AZT/3TC/NVP (PMTCT) vs AZT/3TC/NVP (ART) Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.98 [0.65, 6.03] | 1 study · 244 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen HIV Transmission or Death at 1 Month · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.86 [0.25, 2.97] | 1 study · 218 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.63 [0.38, 1.03] | 1 study · 751 participants | Low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen HIV Transmission or Death at 12 Months · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.86 [0.42, 1.77] | 1 study · 189 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen Infant Mortality at 1 Month · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.33 [0.27, 6.47] | 1 study · 231 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen Maternal Grade 3/4 Severe Adverse Events Requiring Treatment Modification · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 25.33 [1.49, 430.51] | 1 study · 250 participants | Very low |
Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen Infant Low Birth Weight · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 2.17 [1.23, 3.81] | 1 study · 231 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Stillbirths · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.89 [0.26, 3.08] | 1 study · 241 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Maternal Mortality at Delivery · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | no estimate extracted | 1 study · 241 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Mother to Child Transmission of HIV at 1 Month · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.32 [0.04, 2.83] | 1 study · 217 participants | Very low |
Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen Mother to Child Transmission of HIV at 12 Months · HIV‐Infected Pregnant Women Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.4 [0.11, 1.41] | 1 study · 188 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.09 [0.77, 1.53] | 1 study · 824 participants | Very low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 0.95 [0.77, 1.16] | 1 study · 805 participants | Low |
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.23 [0.85, 1.79] | 1 study · 805 participants | Very low |
Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Low Birth Weight · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1.46 [0.94, 2.25] | 1 study · 805 participants | Low |
Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) Stillbirths · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women (2010) · Cochrane | RR 1 [0.25, 3.95] | 1 study · 824 participants | Low |
GnRHas vs No treatment Relief of painful symptoms ‐ Dysmenorrhoea · women with pain associated with endometriosis Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis (2010) · Cochrane | RR 3.93 [1.37, 11.28] | 1 study · 35 participants | Low |
GnRHas vs Placebo Relief of painful symptoms ‐ pelvic tenderness · women with pain associated with endometriosis Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis (2010) · Cochrane | RR 4.17 [1.62, 10.68] | 1 study · 49 participants | Low |
GnRHas vs Placebo Pain score ‐ Overall at 4 weeks · women with pain associated with endometriosis Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis (2010) · Cochrane | no estimate extracted | 1 study · 120 participants | Low |
GnRHas vs Danazol Relief of painful symptoms ‐ Dysmenorrhoea · women with pain due to endometriosis Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis (2010) · Cochrane | RR 0.98 [0.92, 1.04] | 7 studies · 666 participants | Very low |
GnRHas vs Danazol Overall resolution ‐ Overall resolution/improvement · women with pain due to endometriosis Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis (2010) · Cochrane | RR 1.1 [1.01, 1.21] | 9 studies · 1046 participants | Low |
GnRHas vs intra‐ uterine progestogen device Relief of painful symptoms ‐ Overall · women with pain associated with endometriosis Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis (2010) · Cochrane | no estimate extracted | 3 studies · 129 participants | Moderate |
MTX combination vs MTX monotherapy ACR 50 response of DMARDs naive patients Number of responders · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane | RR 1.76 [0.64, 4.85] | 2 studies · 127 participants | Low |
MTX combination vs MTX monotherapy ACR 50 response of MTX inadequate responders number of responders · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane | RR 4.54 [2.51, 8.2] | 3 studies · 404 participants | Moderate |